| 2.42 -0.09 (-3.59%) | 09-04 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 4.99  |
1-year : | 6.34 |
| Resists | First : | 4.27 |
Second : | 5.42 |
| Pivot price | 3.94 |
|||
| Supports | First : | 2.41 | Second : | 2 |
| MAs | MA(5) : | 3 |
MA(20) : | 4.09 |
| MA(100) : | 10.43 |
MA(250) : | 15.46 |
|
| MACD | MACD : | -0.9 |
Signal : | -0.8 |
| %K %D | K(14,3) : | 2.5 |
D(3) : | 7.2 |
| RSI | RSI(14): 25.4 |
|||
| 52-week | High : | 59.7 | Low : | 2.41 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ APUS ] has closed above bottom band by 2.7%. Bollinger Bands are 34.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.6 - 2.62 | 2.62 - 2.64 |
| Low: | 2.37 - 2.4 | 2.4 - 2.42 |
| Close: | 2.39 - 2.42 | 2.42 - 2.44 |
Apimeds Pharmaceuticals US, Inc. provides digital asset treasury solutions in bitcoin treasury infrastructure. The company was incorporated in 2020 and is based in Matawan, New Jersey. Apimeds Pharmaceuticals US, Inc. operates as a subsidiary of Inscobee., Inc.
Mon, 24 Aug 2026
MindWave Innovations (NYSE American: APUS) Helping Corporations Hold, Manage, and Generate Risk-Aware Yield on Bitcoin Reserves - barchart.com
Fri, 21 Aug 2026
Apimeds Pharmaceuticals US Acquires Apitox Royalty and Market Rights From FreeT to Advance U.S. Program - TradingView
Fri, 14 Aug 2026
Apimeds Pharmaceuticals | 10-Q: Q2 2026 Earnings Report - Moomoo
Mon, 03 Aug 2026
NILA Token Now Available to Eligible U.S. Users on Webot, a Licensed U.S. Cryptocurrency Exchange - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
AMEX
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|